Director at Corcept (NASDAQ: CORT) receives 12,500 stock options

Rhea-AI Filing Summary

Corcept Therapeutics director Daniel N. Swisher Jr. received a grant of 12,500 stock options for common stock on May 21, 2026. The options have an exercise price of $59.69 per share and expire on May 21, 2036. They vest in equal monthly installments over one year starting May 21, 2026, conditioned on his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Swisher Daniel N JR

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	12,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 12,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 12,500 options Exercise price: $59.69 per share Underlying shares: 12,500 shares +3 more

6 metrics

Stock options granted 12,500 options Grant to director on May 21, 2026

Exercise price $59.69 per share Stock option exercise price

Underlying shares 12,500 shares Common stock underlying the options

Expiration date May 21, 2036 Option term end date

Vesting schedule Monthly over one year From May 21, 2026, subject to continued service

Options held after grant 12,500 options Total derivative holdings following transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 59.6900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-21T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"Exercisable ratably in equal installments on each monthly anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swisher Daniel N JR

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$59.69	05/21/2026		A		12,500		(1)	05/21/2036	Common Stock	12,500	$0.00	12,500	D

Explanation of Responses:

1. Exercisable ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Daniel N. Swisher, Jr.	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Daniel N. Swisher Jr. acquire in the latest CORT Form 4 filing?

Daniel N. Swisher Jr. received a grant of 12,500 stock options for Corcept Therapeutics common stock. These options represent compensation rather than an open-market purchase, giving him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the new Corcept (CORT) stock options?

The granted stock options carry an exercise price of $59.69 per share. This means Swisher can choose to buy Corcept common stock at $59.69, regardless of the market price, once the options are vested and before they expire.

When do Daniel Swisher’s Corcept stock options vest and over what period?

The options vest ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period. Vesting is conditioned on Swisher’s continued service with Corcept on each monthly vesting date, tying the award to ongoing tenure.

When do the newly granted Corcept (CORT) stock options expire?

The stock options granted to Daniel N. Swisher Jr. expire on May 21, 2036. He must exercise any vested options before that expiration date; otherwise, the right to purchase shares at the fixed exercise price lapses.

How many Corcept stock options does Daniel Swisher hold after this grant?

Following this transaction, Swisher holds 12,500 stock options directly. These options are linked to an equal number of underlying Corcept common shares, providing potential future ownership if he chooses to exercise the award.